Monocrotaline induced Pulmonary Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which is high blood pressure in the lungs.
In rats, a single subcutaneous administration of monocrotaline induces increases in right ventricular (RV) pressure and pulmonary vascular modelling, approximately 4 weeks after monocrotaline administration.
Study Design | |
---|---|
Species/Strain | SD rat |
Model | Monocrotaline induced pulmonary arterial hypertension (PAH) rat model |
Relevant Use | Assessing the efficacy of new compounds for PAH |
Readouts Available | Bodyweights and Clinical Signs, invasive hemodynamic measurements (RVSP), Fulton’s index, histopathology (H&E, van Gieson) |
Study data generated by Labcorp Huntingdon Pharmacology.
Related Models
-
Bhas 42 Cell Transformation Assay (CTA)
Carcinogenicity, Discovery, Toxicology -
Monocrotaline induced Pulmonary Hypertension (PAH)
Discovery -
Asthma: Ovalbumin sensitization and challenge
Discovery -
Chlorine Induced Lung Injury
Discovery -
Methicillin-resistant Staphylococcus aureus (MRSA) neutropenic thigh infection model
Discovery -
COPD: LPS + fMLP PK/PD model – Neutrophil Elastase Targets
Discovery -
COPD: Human Neutrophil Elastase Lung Hemorrhage Model
Discovery -
Bronchoconstriction models for LABA, LAMA & MABAs
Discovery